

## DUR Committee

February 17<sup>th</sup>, 2012 Minutes

### Members Present:

Robert Carlson, M.D. Telephonic  
John Pappenheim, M.D. Telephonic  
William McCormick, Pharm.D. Telephonic  
Mary-Beth Gardner, ANP Telephonic  
Julie Pritchard, Pharm.D. (Magellan)  
C.J. Kim, R.Ph (DHSS)

### Members Absent:

Dharna Begich, Pharm.D.

### Public attendees:

Dan Monahan (Novartis)  
Mary Hennis (Novartis)  
Robert Lynch (Alaska Legal Services)

- Telephonic meeting started at 1:00pm and roll call.
- Review of minutes from previous meeting.
- Review agenda for additions or comments.

### ProDUR

- Proposed prior authorizations:
  - **Flector Patches** was discussed for regarding usage and informed committee that it will be a Non-preferred medication and does not require a PA. For quantities prescribed over the proposed quantity limits it would have to go through an appeal process and possibility with supporting documentation it could be overridden, passed unanimously.
  - Informed committee of two other topical analgesics (Voltaren Gel and Pennsaid solution) that usage and quantities being dispensed did not merit a quantity limit.
  - **Adderall XR** was discussed for regarding usage. Committee initially agreed on proposed quantity limits but wanted to expand the quantity limits for consideration of other diagnoses and factors. Such as adult ADHD, body mass, age, and other appropriate dosing those adults might require. The committee wanted to address these issues before rendering a final decision. Julie will research additional information and coding that other states might be using. Committee members will also submit possible exclusion criteria for review next meeting in April. All proposed quantity limits for stimulants are tabled until the meeting in April. The stimulant criteria and quantity limits will then be reevaluated in April.
- Review of New Prescription Medications (medications that have been on the Interim Prior Authorization for a minimum of six months):
  - Arzerra, and Flo-Pred to be removed, passed unanimously.
  - Xareto, ‘No Action – leave under current PA’, passed unanimously.
- Break 1:40pm
- Return 1:50pm
- Informed committee of new recent PA for Egrifta that no claims were made.
- Informed committee of new recent PA for Cialis for BPH that there were claims attempted, but no paid claims at this time.

### Retrospective DUR

- Discuss review criteria
- **Retrospective DUR** (amphetamines and duplication of therapy with other CNS stimulants).
  - The profiles were discussed and evaluated for intervention letters to be sent out to the providers.
  - Based on the criteria, only 7 out of 40 profiles reviewed will get letters. Some providers will receive polypharmacy, polyproviders and possible lock-in referral.
- Dr. Pappenheim left the meeting at 2:13pm.
- Dr. Carlson suggested possible topic for future DUR is triptans and cardiovascular medications.
- Next meeting is scheduled for March 16, 2012 and location TBD.
- Meeting adjourned 2:21pm.